This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Xeljanz®(tofacitinib citrate) Prescribing information and Inflectra®(infliximab) Prescribing information. Adverse event reporting can be found at the bottom of the page.
Ulcerative Colitis (UC) is the most common form of Inflammatory Bowel Disease (IBD).1
IBD is a group of disorders that cause chronic inflammation in the GI tract. Inflammation leads to damage of GI organs and impairs their ability to function properly. The most common forms of IBD are UC and Crohn's Disease (CD)
The exact cause of IBD is unkown; however, it is thought to involve interactions between genes, the immune system, and environmental factors.
In UC, ongoing inflammation is limited to the large intestine (colon) and rectum and affects only the innermost lining of these organs2. Inflammation leads to the formation of ulcers (sores) that can bleed and result in bloody stools, the hallmark symptom of UC2,5
Click on the drop downs below to learn about key demographic characteristics of Ulcerative Colitis
1. National Institute of Diabetes and Digestive and Kidney Diseases. [Document on the Internet]. 2016 Jan 1 [cited 2016 Dec 13]. Available from: https://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0022855/
2. Crohn’s and Colitis Foundation of America. The facts about inflammatory bowel diseases. 2014. [Document on the Internet]. 2014 Jan 1 [cited 2016 Dec 14]. Available from: http://www.ccfa.org/assets/pdfs/updatedibdfactbook.pdf.
3. Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011; 365:1713-1725.
4. Molodecky NA, Soon IS, Rabi DM. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012; 142(1):46-54.
5. Ordás I. Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet. 2012; 380:1606-1619.
Click below to view the Immuno-navigator tool. An interactive tool to help you manage discussions with your patients .
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2023 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021